Biomarker comparison between androgen receptor positive-triple-negative breast cancer (AR + TNBC) and quadruple-negative breast cancer (QNBC)


Joanne Xiu, PhD; Elias Obeid, MD; Zoran Gatalica, MD, Dsc; Sandeep Reddy, MD, Lori J. Goldstein, MD; John Link, MD; James Waisman, MD


Quadruple-negative breast cancer (QNBC) is a subgroup of triplenegative breast cancer (TNBC) that lacks androgen receptor (AR) expression. While TNBC patients with AR expression have shown a promising response to AR-targeted therapies, QNBC patients’ treatment options remain limited, with no targeted therapy. We investigated the biomarker profiles of large cohorts of AR+TNBC and QNBC to identify their molecular differences.

Download Publication